Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.48 |
| ▸ | PDCD4 | Q53EL6 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163935 | 0.85 | CA1 (0.68) | CA1CA2POLBTARBP2PDCD4 | |
| SCHEMBL11485622 | 0.84 | CA1 (0.67) | CA1CA2POLBLMNATARBP2 | |
| SCHEMBL167291 | 0.83 | CA1 (0.68) | CA1CA2POLBLMNATARBP2 | |
| SCHEMBL326764 | 0.83 | CA1 (0.71) | CA1CA2POLBTARBP2PDCD4 | |
| SCHEMBL27851526 | 0.83 | KCNH2 (0.49) | POLBLMNAMAPTHSD17B10ALDH1A1 | |
| SCHEMBL28501879 | 0.80 | CA1 (0.68) | CA1CA2POLBLMNATARBP2 | |
| SCHEMBL7865590 | 0.80 | CA1 (0.72) | CA1CA2POLBLMNATARBP2 | |
| SCHEMBL165878 | 0.80 | POLB (0.76) | CA1CA2POLBLMNATARBP2 | |
| SCHEMBL31049616 | 0.80 | CA1 (0.68) | CA1CA2POLBTARBP2PDCD4 | |
| SCHEMBL22658109 | 0.80 | TARBP2 (0.51) | POLBLMNATARBP2PDCD4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424870-B1 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2015-12-16 | — | — | EP | disclosed |
| EP-2590969-B1 | Therapeutic agents 976 | ASTRAZENECA AB (SE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2590969-B1 | Therapeutic agents 976 | ASTRAZENECA AB (SE) | 2014-10-15 | — | — | EP | disclosed |
| US-8546375-B2 | (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds | ASTRAZENECA AB (SE) | 2013-10-01 | — | — | US | disclosed |
| US-8546375-B2 | (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds | ASTRAZENECA AB (SE) | 2013-10-01 | — | — | US | disclosed |
| US-8546375-B2 | (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds | ASTRAZENECA AB (SE) | 2013-10-01 | — | — | US | disclosed |
| EP-2590969-A2 | THERAPEUTIC AGENTS 976 | AstraZeneca AB (SE) | 2013-05-15 | — | — | EP | disclosed |
| EP-2424870-A1 | THERAPEUTIC AGENTS 713 | AstraZeneca AB (SE) | 2012-03-07 | — | — | EP | disclosed |
| US-8110566-B2 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2012-02-07 | — | — | US | disclosed |
| US-8110566-B2 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2012-02-07 | — | — | US | disclosed |
| WO-2012004588-A2 | THERAPEUTIC AGENTS 976 | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004588-A2 | THERAPEUTIC AGENTS 976 | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | US | disclosed |
| WO-2010125390-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125390-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280000-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280000-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280000-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280000-A1 | THERAPEUTIC AGENTS 713 | MC1R, MC2R, MC3R | CA1 2214/4885CA2 2731/4885POLB 3052/4885 |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | TYR, MC2R, MC1R | CA1 4828/4885CA2 4291/4885POLB 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.